| Homology Modeling of the Serotonin 5-HT1A Receptor Using Automated Docking of Bioactive Compounds with Defined Geometry M Nowak, M Kołaczkowski, M Pawłowski, AJ Bojarski Journal of medicinal chemistry 49 (1), 205-214, 2006 | 114 | 2006 |
| Receptor-Based Pharmacophores for Serotonin 5-HT7R AntagonistsImplications to Selectivity M Kołaczkowski, M Nowak, M Pawłowski, AJ Bojarski Journal of medicinal chemistry 49 (23), 6732-6741, 2006 | 96 | 2006 |
| Novel multi-target-directed ligands for Alzheimer's disease: combining cholinesterase inhibitors and 5-HT6 receptor antagonists. Design, synthesis and biological evaluation A Więckowska, M Kołaczkowski, A Bucki, J Godyń, M Marcinkowska, ... European Journal of Medicinal Chemistry 124, 63-81, 2016 | 84 | 2016 |
| Studies on the anticonvulsant activity of 4-alkyl-1, 2, 4-triazole-3-thiones and their effect on GABAergic system T Plech, B Kaproń, JJ Łuszczki, A Paneth, A Siwek, M Kołaczkowski, ... European Journal of Medicinal Chemistry 86, 690-699, 2014 | 76 | 2014 |
| Ligand-Optimized Homology Models of D1 and D2 Dopamine Receptors: Application for Virtual Screening M Kołaczkowski, A Bucki, M Feder, M Pawłowski Journal of chemical information and modeling 53 (3), 638-648, 2013 | 73 | 2013 |
| Novel Arylsulfonamide Derivatives with 5-HT6/5-HT7 Receptor Antagonism Targeting Behavioral and Psychological Symptoms of Dementia M Kołaczkowski, M Marcinkowska, A Bucki, M Pawłowski, K Mitka, ... Journal of medicinal chemistry 57 (11), 4543-4557, 2014 | 68 | 2014 |
| Metabolic carbonyl reduction of anthracyclines—role in cardiotoxicity and cancer resistance. Reducing enzymes as putative targets for novel cardioprotective and … K Piska, P Koczurkiewicz, A Bucki, K Wójcik-Pszczoła, M Kołaczkowski, ... Investigational new drugs 35, 375-385, 2017 | 64 | 2017 |
| Sweet liking in patients with Parkinson's disease H Sienkiewicz-Jarosz, A Scinska, L Swiecicki, W Lipczynska-Lojkowska, ... Journal of the neurological sciences 329 (1-2), 17-22, 2013 | 58 | 2013 |
| Activity of Serotonin 5-HT1A Receptor Biased Agonists in Rat: Anxiolytic and Antidepressant-like properties M Jastrzębska-Więsek, A Partyka, J Rychtyk, J Śniecikowska, ... ACS chemical neuroscience 9 (5), 1040-1050, 2017 | 57 | 2017 |
| Novel multitarget-directed ligands aiming at symptoms and causes of Alzheimer’s disease A Wieckowska, T Wichur, J Godyń, A Bucki, M Marcinkowska, A Siwek, ... ACS chemical neuroscience 9 (5), 1195-1214, 2018 | 54 | 2018 |
| Studies on the anticonvulsant activity and influence on GABA-ergic neurotransmission of 1, 2, 4-triazole-3-thione-based compounds T Plech, B Kaproń, JJ Łuszczki, M Wujec, A Paneth, A Siwek, ... Molecules 19 (8), 11279-11299, 2014 | 51 | 2014 |
| Synthesis and pharmacological evaluation of new 5-(cyclo) alkyl-5-phenyl-and 5-spiroimidazolidine-2, 4-dione derivatives. Novel 5-HT1A receptor agonist with potential … A Czopek, H Byrtus, M Kołaczkowski, M Pawłowski, M Dybała, G Nowak, ... European journal of medicinal chemistry 45 (4), 1295-1303, 2010 | 47 | 2010 |
| Synthesis, anticonvulsant activity and 5-HT1A, 5-HT2A receptor affinity of new N-[(4-arylpiperazin-1-yl)-alkyl] derivatives of 2-azaspiro [4.4] nonane and [4.5] decane-1, 3-dione J Obniska, M Kołaczkowski, AJ Bojarski, B Duszyńska European journal of medicinal chemistry 41 (7), 874-881, 2006 | 46 | 2006 |
| The impact of spacer structure on 5-HT7 and 5-HT1A receptor affinity in the group of long-chain arylpiperazine ligands AJ Bojarski, B Duszyńska, M Kołaczkowski, P Kowalski, T Kowalska Bioorganic & medicinal chemistry letters 14 (23), 5863-5866, 2004 | 46 | 2004 |
| Management of dementia-related psychosis, agitation and aggression: a review of the pharmacology and clinical effects of potential drug candidates M Marcinkowska, J Śniecikowska, N Fajkis, P Paśko, W Franczyk, ... CNS drugs 34 (3), 243-268, 2020 | 45 | 2020 |
| Novel butanehydrazide derivatives of purine-2, 6-dione as dual PDE4/7 inhibitors with potential anti-inflammatory activity: design, synthesis and biological evaluation G Chłoń-Rzepa, A Jankowska, M Ślusarczyk, A Świerczek, K Pociecha, ... European journal of medicinal chemistry 146, 381-394, 2018 | 44 | 2018 |
| Antinociceptive, antiallodynic and antihyperalgesic effects of the 5-HT1A receptor selective agonist, NLX-112 in mouse models of pain K Sałat, M Kołaczkowski, A Furgała, A Rojek, J Śniecikowska, MA Varney, ... Neuropharmacology 125, 181-188, 2017 | 43 | 2017 |
| Translating biased agonists from molecules to medications: Serotonin 5-HT1A receptor functional selectivity for CNS disorders A Newman-Tancredi, RY Depoortère, MS Kleven, M Kołaczkowski, ... Pharmacology & Therapeutics 229, 107937, 2022 | 42 | 2022 |
| Antipsychotic, antidepressant, and cognitive-impairment properties of antipsychotics: rat profile and implications for behavioral and psychological symptoms of dementia M Kołaczkowski, P Mierzejewski, P Bienkowski, A Wesołowska, ... Naunyn-Schmiedeberg's archives of pharmacology 387, 545-557, 2014 | 42 | 2014 |
| Idalopirdine – a small molecule antagonist of 5-HT6 with therapeutic potential against obesity M Dudek, M Marcinkowska, A Bucki, A Olczyk, M Kołaczkowski Metabolic Brain Disease 30, 1487-1494, 2015 | 39 | 2015 |
